Philogen Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Dario Neri

Chief executive officer

€150.0k

Total compensation

CEO salary percentage	n/a
CEO tenure	28.4yrs
CEO ownership	n/a
Management average tenure	no data
Board average tenure	no data

Recent management updates

Recent updates

Analyst Forecasts For Philogen S.p.A. (BIT:PHIL) Are Surging Higher

Apr 14

Earnings Update: Philogen S.p.A. (BIT:PHIL) Just Reported And Analysts Are Boosting Their Estimates

Mar 31

What Philogen S.p.A.'s (BIT:PHIL) P/S Is Not Telling You

Feb 24

Here's Why We're Watching Philogen's (BIT:PHIL) Cash Burn Situation

Jun 03

CEO

Dario Neri (61 yo)

28.4yrs

Tenure

€150,000

Compensation

Prof. Dr. Dario Neri, PhD co-founded Philogen S.p.A in 1996 and serves as its CSO, President of The Scientific Advisory Board and Chief Executive Officer and Managing Director. Prof. Dr. Neri served as Sc...

Philogen Management

Management criteria checks 2/4

Key information

Recent management updates

Director recently bought €179k worth of stock

Less than half of directors are independent

Less than half of directors are independent

Director recently bought €377k worth of stock

Director recently bought €4.7m worth of stock

Director recently bought €4.4m worth of stock

Recent updates

Director recently bought €179k worth of stock

Analyst Forecasts For Philogen S.p.A. (BIT:PHIL) Are Surging Higher

Consensus revenue estimates increase by 314%

Consensus revenue estimates fall by 76%

Earnings Update: Philogen S.p.A. (BIT:PHIL) Just Reported And Analysts Are Boosting Their Estimates

New major risk - Financial position

Full year 2023 earnings released

What Philogen S.p.A.'s (BIT:PHIL) P/S Is Not Telling You

Philogen S.p.A. Provides Update on Pre-Planned Interim Analysis of the Phase III FIBROSARC Trial Investigating Onfekafusp Alfa in Patients with First-Line Advanced or Metastatic Soft Tissue Sarcoma

Philogen S.p.A. to Report Fiscal Year 2023 Results on Mar 27, 2024

Philogen S.P.A. Announces Receipt of the Good Manufacturing Practice Certificate for Its New Production Facility in Rosia (Siena, Italy) by Competent Authorities

New major risk - Revenue and earnings growth

Philogen S.P.A. and Sun Pharmaceutical Industries Limited Announces Positive Results from the Phase III Pivotal Trial in Patients with Locally Advanced Fully Ressectable Melanoma

First half 2023 earnings released: EPS: €0.19 (vs €0.049 in 1H 2022)

Philogen S.p.A. (BIT:PHIL) commences an Equity Buyback Plan for 500,000 shares, representing 1.23% of its issued share capital, under the authorization approved on April 28, 2023.

Less than half of directors are independent

First half 2022 earnings released: EPS: €0 (vs €0.21 loss in 1H 2021)

Price target decreased to €16.50

Philogen S.p.A. Announces Enrolment of 214 Patients in the Nidlegy Phase III European Clinical Trial for the Treatment of Locally Advanced Melanoma

Consensus forecasts updated

Less than half of directors are independent

Consensus revenue estimates increase by 475%

Price target increased to €24.00

Full year 2021 earnings: Revenues exceed analyst expectations

Director recently bought €377k worth of stock

Director recently bought €4.7m worth of stock

Director recently bought €4.4m worth of stock

Philogen S.p.A. Announces R&D Program Update

Here's Why We're Watching Philogen's (BIT:PHIL) Cash Burn Situation

CEO

Tenure

Compensation